Pelage Pharmaceuticals, Inc. filed a Form D with the Securities and Exchange Commission on 2025-11-24.
Pelage Pharmaceuticals, Inc. filed a Form D notice of an exempt securities offering with the SEC on November 24, 2025. The filing reports $120M sold. Its industry group is Pharmaceuticals. It names Daniel Gil (Executive Officer, Director), William Lowry (Executive Officer, Director), Nathan Wheeler (Executive Officer) (SEC Form D, November 24, 2025).
Is this your company?
Sell to companies like Pelage Pharmaceuticals, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
New Form D on file · 2025-11-24 · the record
Pitching, partnering or investing alongside them? See who really runs and owns Pelage Pharmaceuticals, Inc.
Free to see. No signup.
More on the people and the money behind Pelage Pharmaceuticals, Inc., from the filings we hold.
Pharmaceuticals raises by companies based in California, filed in November 2025, largest first.
Get an email when Pelage Pharmaceuticals, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
We'll show it in your MentionFox inbox when Pelage Pharmaceuticals, Inc. raises, hires or launches. No email unless you switch it on.
Watch Pelage Pharmaceuticals, Inc. →Get the full cited report on Pelage Pharmaceuticals, Inc.
What the filing shows about Pelage Pharmaceuticals, Inc.
Only in the Full Report: Who Runs It, And How To Reach Them · Warning Bells · Who Pays Them, And Who They Are Up Against.
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on Pelage Pharmaceuticals, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
The filing gives Pelage Pharmaceuticals, Inc.'s address as 907 Westwood Blvd #384, Los Angeles, CA 90024.
Saved here on this device in the meantime, so nothing is lost either way.
This is the company's own disclosure. A payment disclosed on a Form D is a disclosed use of proceeds, not a finding of wrongdoing.
Order the Full Report on Pelage Pharmaceuticals, Inc. See pricing
Pelage Pharmaceuticals, Inc. is a registered filer with the SEC (CIK 1982875) and has filed since 2023-06-28. 3 filings are on record, the latest on 2025-11-24.
A filing shows the company exists and what it reports about itself. It is not an audit or a rating.
Pelage Pharmaceuticals, Inc.'s Form D of 2025-11-24 names Daniel Gil, William Lowry, Nathan Wheeler and 3 more as its officers, directors or promoters.
Its new offerings report $150.75M sold across 3 offerings, as its own filings state.
Each marker is one filing. The larger marker is the filing this page is about.
Trailing twelve months. 155 filings in Pharmaceuticals, totalled by week. The dot is this raise, $120M, on the same scale — one filing against the whole group's total, so it sits low by construction.
Daniel Gil is named as Executive Officer and Director on the Form D that Pelage Pharmaceuticals, Inc. filed with the SEC on 24 November 2025, one of 6 people that filing names.
William Lowry is named as Executive Officer and Director on the Form D that Pelage Pharmaceuticals, Inc. filed with the SEC on 24 November 2025, one of 6 people that filing names.
Nathan Wheeler is named as Executive Officer on the Form D that Pelage Pharmaceuticals, Inc. filed with the SEC on 24 November 2025, one of 6 people that filing names.
Cathy Friedman is named as Director on the Form D that Pelage Pharmaceuticals, Inc. filed with the SEC on 24 November 2025, one of 6 people that filing names.
Richard Heyman is named as Director on the Form D that Pelage Pharmaceuticals, Inc. filed with the SEC on 24 November 2025, one of 6 people that filing names.
Christina Weng is named as Executive Officer on the Form D that Pelage Pharmaceuticals, Inc. filed with the SEC on 24 November 2025, one of 6 people that filing names.
6 people named on the filing — 4 holding an executive role and 2 as directors only.
Named as of the 2025-11-24 filing. Titles and locations are exactly as the filing states — not independently confirmed elsewhere.
No investor is drawn from a Form D — the form states how many invested and never who.
What the filing shows about Pelage Pharmaceuticals, Inc.
Only in the Full Report: Who Runs It, And How To Reach Them · Warning Bells · Who Pays Them, And Who They Are Up Against.
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on Pelage Pharmaceuticals, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Pelage Pharmaceuticals, Inc. covers
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
You land back on this company when you are in.
Not ready to upgrade? Keep this one in view instead.
Watchlist Pelage Pharmaceuticals, Inc.You get an alert in MentionFox the next time this company shows up.
If you're behind Pelage Pharmaceuticals, Inc.: the weeks after a raise are watched the same way — by other investors sizing you up, and by founders checking who just got funded. FoxPlug turns your commits, deploys, and releases into that story automatically. GetFoxChat puts a guide on your own site so the people this filing just sent you don't leave after one page.
Sourced from the filing index on sec.gov.
Each opens in a new tab, filled in for Pelage Pharmaceuticals, Inc.. With no account yet, you sign up free and land on the result.
On these lists: Pharmaceuticals raises in Los Angeles
Share your raise. This card is drawn from the company's own Form D filing, and sharing needs no account.
https://mentionfox.com/funding/pelage-pharmaceuticals-inc-form-d-25000001